Trial Profile
Phase 2 Randomized Study of Efficacy and Safety of Testosterone in Metastatic Renal Cell Carcinoma Patients With Fatigue
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Testosterone undecanoate (Primary) ; Pazopanib; Sunitinib
- Indications Fatigue
- Focus Therapeutic Use
- Acronyms FARETES
- 01 Apr 2021 Primary endpoint (Fatigue) has been met.
- 01 Apr 2021 Results published in the American Journal of Clinical Oncology.
- 18 Oct 2019 Status changed from active, no longer recruiting to completed.